{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:01:37Z","timestamp":1790341297580,"version":"4.1.0"},"reference-count":97,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is the most common liver cancer and usually develops on a background of cirrhotic liver. Early and accurate diagnosis enables potentially curative interventions. HCC surveillance, usually offered to patients at risk for HCC, such as those with cirrhosis, chronic hepatitis B infection, and previous diagnosis of HCC, is associated with earlier detection and improved survival. In these patients, the diagnosis can be established non-invasively without histological confirmation when the imaging-based LI-RADS criteria are met. Tissue biopsy is mandatory for establishing diagnosis in patients without cirrhosis or other risk factors for HCC, differentiating HCC from other malignant and non-malignant entities, especially when imaging features are not conclusive. In this review, we discuss the evolving role of tissue biopsy beyond establishing the diagnosis, in providing important prognostic information and enabling precise histopathological classification. Features such as poor differentiation, microvascular invasion, and a pattern of vessels encapsulating tumor clusters are linked to worse prognosis. HCC is characterized by heterogeneity, with different histological subtypes associated with distinct clinical and radiological features and distinct biology. Emerging data from molecular profiling and immune-microenvironment studies enable further classification into proliferative versus non-proliferative molecular subgroups and inflamed versus non-inflamed immune subtypes. This more refined characterization of HCC carries important implications not only for prognostication but also for predicting response to immunotherapy. In the future, the combination of imaging features that correlate with molecular signatures, novel serum biomarkers, and liquid biopsy may provide less invasive tools for early detection, risk stratification, and guide personalized therapeutic strategies.<\/jats:p>","DOI":"10.3390\/cancers18193115","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:31:44Z","timestamp":1790339504000},"page":"3115","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Rationale for Tissue Biopsy in the Era of Precision Hepatocellular Carcinoma Management"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6042-6554","authenticated-orcid":false,"given":"Ioanna-Maria","family":"Grypari","sequence":"first","affiliation":[{"name":"Pathology Department, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina G.","family":"Tiniakos","sequence":"additional","affiliation":[{"name":"Department of Pathology, Aretaeion Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece"},{"name":"Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE1 7RU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kalafateli","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"},{"name":"Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London W2 1NY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8136-3927","authenticated-orcid":false,"given":"Eleni","family":"Theocharidou","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","article-title":"Global Epidemiology and Genetics of Hepatocellular Carcinoma","volume":"164","author":"Toh","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","author":"Sangro","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","article-title":"HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis","volume":"77","author":"Singal","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.32604\/or.2026.076937","article-title":"Current and Future Landscape of Hepatocellular Carcinoma Treatment","volume":"34","author":"Zerehpoosh","year":"2026","journal-title":"Oncol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A Model to Predict Survival in Patients With End\u2013Stage Liver Disease","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa0801209","article-title":"Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting List","volume":"359","author":"Kim","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach\u2014The ALBI Grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1016\/S1470-2045(23)00186-9","article-title":"Personalised management of patients with hepatocellular carcinoma: A multiparametric therapeutic hierarchy concept","volume":"24","author":"Vitale","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1148\/radiol.2018181494","article-title":"Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients","volume":"289","author":"Chernyak","year":"2018","journal-title":"Radiology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1055\/s-0042-124661","article-title":"American College of Radiology Contrast Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for the diagnosis of Hepatocellular Carcinoma: A pictorial essay","volume":"38","author":"Piscaglia","year":"2017","journal-title":"Ultraschall der Med.\u2014Eur. J. Ultrasound"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","article-title":"Incidence of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression","volume":"20","author":"Orci","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hep.32341","article-title":"HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis","volume":"76","author":"Lockart","year":"2022","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/HEP.0000000000000339","article-title":"Screening of liver cancer with abbreviated MRI","volume":"78","author":"Ronot","year":"2023","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100390","DOI":"10.1016\/j.jhepr.2021.100390","article-title":"Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis","volume":"4","author":"Nahon","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"International Consensus Group for Hepatocellular Neoplasia (2008). Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia. Hepatology, 49, 658\u2013664.","DOI":"10.1002\/hep.22709"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100364","DOI":"10.1016\/j.jhepr.2021.100364","article-title":"Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B","volume":"3","author":"Lewis","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/liv.13429","article-title":"EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice","volume":"37","author":"Oberti","year":"2017","journal-title":"Liver Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/hep.29487","article-title":"Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis","volume":"67","author":"Roberts","year":"2018","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"20180345","DOI":"10.1259\/bjr.20180345","article-title":"Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: Effect of hepatic steatosis on major hepatocellular carcinoma features at MRI","volume":"91","author":"Thompson","year":"2018","journal-title":"Br. J. Radiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/jmri.27783","article-title":"Hepatic Steatosis Has No Effect in Diagnosis Accuracy of LI-RADS v2018 Categorization of Hepatocellular Carcinoma in MR Imaging","volume":"59","author":"Yao","year":"2021","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jhep.2019.12.011","article-title":"Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs","volume":"72","author":"Paisant","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"W63","DOI":"10.2214\/AJR.17.18300","article-title":"Performing Gadoxetic Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis","volume":"210","author":"Suh","year":"2018","journal-title":"Am. J. Roentgenol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.cgh.2021.11.042","article-title":"Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations","volume":"21","author":"Arvind","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/liv.14223","article-title":"Biology and significance of alpha-fetoprotein in hepatocellular carcinoma","volume":"39","author":"Galle","year":"2019","journal-title":"Liver Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1007\/s00330-025-12075-1","article-title":"Imaging for molecular and pathological subtyping of hepatocellular carcinoma\u2014A critical appraisal and future directions","volume":"36","author":"Jia","year":"2025","journal-title":"Eur. Radiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"103184","DOI":"10.1016\/j.jceh.2025.103184","article-title":"Artificial Intelligence for Predictive Diagnostics, Prognosis, and Decision Support in MASLD, Hepatocellular Carcinoma, and Digital Pathology","volume":"16","author":"Dunn","year":"2025","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Chartampilas, E., Rafailidis, V., Georgopoulou, V., Kalarakis, G., Hatzidakis, A., and Prassopoulos, P. (2022). Current Imaging Diagnosis of Hepatocellular Carcinoma. Cancers, 14.","DOI":"10.3390\/cancers14163997"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3348\/kjr.2018.0636","article-title":"Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging","volume":"20","author":"Kim","year":"2019","journal-title":"Korean J. Radiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.3748\/wjg.v25.i40.6041","article-title":"Role of liver biopsy in hepatocellular carcinoma","volume":"25","author":"Spadaccini","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3350\/cmh.2015.21.4.326","article-title":"Imaging findings of mimickers of hepatocellular carcinoma","volume":"21","author":"Kim","year":"2015","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1007\/s00330-019-06030-0","article-title":"Problematic lesions in cirrhotic liver mimicking hepatocellular carcinoma","volume":"29","author":"Kim","year":"2019","journal-title":"Eur. Radiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.5858\/arpa.2020-0047-RA","article-title":"Recent Advances in Digestive Tract Tumors: Updates From the 5th Edition of the World Health Organization \u201cBlue Book\u201d","volume":"145","author":"Gonzalez","year":"2020","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"112271","DOI":"10.1016\/j.ejrad.2025.112271","article-title":"Role of imaging-guided biopsy for hepatocellular carcinoma","volume":"191","author":"Cannella","year":"2025","journal-title":"Eur. J. Radiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2017.05.014","article-title":"Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification","volume":"67","author":"Calderaro","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jhep.2023.11.030","article-title":"Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma","volume":"80","author":"Lehrich","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Chun, S.J., Yoo, J.-J., Kim, S.G., and Kim, Y.-S. (2025). Current Trends and Impact of Liver Biopsy on Survival in Hepatocellular Carcinoma: A Korean Multicenter Analysis. Diagnostics, 15.","DOI":"10.3390\/diagnostics15070818"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Sp\u00e2rchez, Z., Cr\u0103ciun, R., Nenu, I., Mocan, L.P., Sp\u00e2rchez, M., and Mocan, T. (2023). Refining Liver Biopsy in Hepatocellular Carcinoma: An In-Depth Exploration of Shifting Diagnostic and Therapeutic Applications. Biomedicines, 11.","DOI":"10.3390\/biomedicines11082324"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1159\/000533328","article-title":"Liver Biopsy: To Do or Not to Do\u2014A Single-Center Study","volume":"41","author":"Androutsakos","year":"2023","journal-title":"Dig. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4254\/wjh.v10.i7.452","article-title":"Contemporary role of liver biopsy in hepatocellular carcinoma","volume":"10","author":"Sparchez","year":"2018","journal-title":"World J. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1007\/s10620-023-08071-4","article-title":"Technical Success, Sample Adequacy, and Complications of Pediatric Transjugular Liver Biopsy: A Systematic Review and Meta-Analysis","volume":"68","author":"Smayra","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1055\/s-0044-1792174","article-title":"Image-Guided Liver Biopsy: Perspectives from Interventional Radiology","volume":"41","author":"Ma","year":"2024","journal-title":"Semin. Interv. Radiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/gutjnl-2020-321299","article-title":"Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology","volume":"69","author":"Neuberger","year":"2020","journal-title":"Gut"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/his.70116","article-title":"Changes in the 6th edition of the World Health Organization classification of tumours of the digestive system","volume":"88","author":"Arends","year":"2026","journal-title":"Histopathology"},{"key":"ref_47","first-page":"249","article-title":"Torbenson MS Hepatocellular Carcinoma","volume":"Volume 1","author":"Esposito","year":"2026","journal-title":"WHO Classification of Digestive System Tumours"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jhep.2024.06.004","article-title":"Rare primary liver cancers: An EASL position paper","volume":"81","author":"Wege","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jhep.2026.01.015","article-title":"Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma","volume":"84","author":"Nault","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1007\/s00330-022-08643-4","article-title":"MRI features of histologic subtypes of hepatocellular carcinoma: Correlation with histologic, genetic, and molecular biologic classification","volume":"32","author":"Yoon","year":"2022","journal-title":"Eur. Radiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1148\/rg.210206","article-title":"Morphomolecular Classification Update on Hepatocellular Adenoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma","volume":"42","author":"Katabathina","year":"2022","journal-title":"RadioGraphics"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/modpathol.2015.4","article-title":"DNAJB1-PRKACA is specific for fibrolamellar carcinoma","volume":"28","author":"Graham","year":"2015","journal-title":"Lab. Investig."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/modpathol.2014.78","article-title":"mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma","volume":"28","author":"Riehle","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"051","DOI":"10.1055\/s-0037-1621710","article-title":"Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms","volume":"38","author":"Lalazar","year":"2018","journal-title":"Semin. Liver Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1038\/s41591-025-03995-y","article-title":"A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: A phase 1 trial","volume":"31","author":"Baretti","year":"2025","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1007\/s00261-024-04773-z","article-title":"Magnetic resonance imaging of hepatocellular carcinoma: A spectrum of uncommon morphologic subtypes, unusual imaging patterns and mimics","volume":"50","author":"Wang","year":"2025","journal-title":"Abdom. Radiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jhep.2020.08.013","article-title":"Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications","volume":"74","author":"Rhee","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.29762","article-title":"Macrotrabecular-massive hepatocellular carcinoma","volume":"68","author":"Ziol","year":"2018","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"152134","DOI":"10.1016\/j.anndiagpath.2023.152134","article-title":"Histological subtypes of hepatocellular carcinoma: Their clinical and prognostic significance","volume":"64","author":"Shin","year":"2023","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_60","first-page":"194","article-title":"Carcinome h\u00e9patocellulaire: Classifications histologiques et mol\u00e9culaires","volume":"45","author":"Paradis","year":"2024","journal-title":"Ann. de Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.humpath.2011.07.005","article-title":"The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis","volume":"43","author":"Salomao","year":"2012","journal-title":"Hum. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.humpath.2020.12.009","article-title":"Hepatocellular carcinoma: Making sense of morphological heterogeneity, growth patterns, and subtypes","volume":"112","author":"Torbenson","year":"2020","journal-title":"Hum. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/liv.15589","article-title":"Steatotic hepatocellular carcinoma: Association of MRI findings to underlying liver disease and clinicopathological characteristics","volume":"43","author":"Park","year":"2023","journal-title":"Liver Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/his.14941","article-title":"Pathological overview of steatohepatitic hepatocellular carcinoma in a surgical series","volume":"83","author":"Trapani","year":"2023","journal-title":"Histopathology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"100809","DOI":"10.1016\/j.neo.2022.100809","article-title":"Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"30","author":"Petrelli","year":"2022","journal-title":"Neoplasia"},{"key":"ref_66","first-page":"38","article-title":"Steatohepatitic hepatocellular carcinoma","volume":"7","author":"Torbenson","year":"2021","journal-title":"Hepatoma Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/PAS.0b013e3182495c73","article-title":"Reticulin Loss in Benign Fatty Liver","volume":"36","author":"Singhi","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"391","DOI":"10.14740\/gr1110","article-title":"Steatohepatitic Variant of Hepatocellular Carcinoma: A Focused Review","volume":"11","author":"Olofson","year":"2018","journal-title":"Gastroenterol. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.17998\/jlc.20.1.17","article-title":"Histopathological Variants of Hepatocellular Carcinomas: An Update According to the 5th Edition of the WHO Classification of Digestive System Tumors","volume":"20","author":"Kim","year":"2020","journal-title":"J. Liver Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Choi, J.H., and Thung, S.N. (2023). Advances in Histological and Molecular Classification of Hepatocellular Carcinoma. Biomedicines, 11.","DOI":"10.3390\/biomedicines11092582"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/modpathol.2012.243","article-title":"Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma","volume":"26","author":"Krings","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1007\/s00330-017-5196-y","article-title":"Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging","volume":"28","author":"Choi","year":"2018","journal-title":"Eur. Radiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/RCT.0b013e31829d44c1","article-title":"Scirrhous Hepatocellular Carcinoma on Gadoxetic Acid\u2013Enhanced Magnetic Resonance Imaging and Diffusion-Weighted Imaging","volume":"37","author":"Park","year":"2013","journal-title":"J. Comput. Assist. Tomogr."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s12072-021-10146-1","article-title":"Clinical manifestations and outcomes of patients with scirrhous hepatocellular carcinoma","volume":"15","author":"Huang","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12957-017-1144-1","article-title":"IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing","volume":"15","author":"Lee","year":"2017","journal-title":"World J. Surg. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12967-025-07354-w","article-title":"Vessels encapsulating tumor clusters in hepatocellular carcinoma: A distinct metastatic pathway with diagnostic and therapeutic significance","volume":"24","author":"Zhu","year":"2026","journal-title":"J. Transl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"100792","DOI":"10.1016\/j.jhepr.2023.100792","article-title":"Vessels that encapsulate tumour clusters vascular pattern in hepatocellular carcinoma","volume":"5","author":"Liu","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"110381","DOI":"10.1016\/j.ejso.2025.110381","article-title":"Immunological and prognostic significance of vessels encapsulating tumor clusters (VETC) in hepatocellular carcinoma","volume":"51","author":"Taniai","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.1038\/s41467-026-73212-y","article-title":"Integrated genomic analyses identify oncogenic pathway interplay in hepatocarcinogenesis defining specific molecular subtypes","volume":"17","author":"Pan","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s12094-024-03427-2","article-title":"The prognostic value of vessels encapsulating tumor clusters (VETC) in patients with hepatocellular carcinoma: A systematic review and meta-analysis","volume":"26","author":"Wang","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Dennis, C., Prince, D.S., Moayed-Alaei, L., Remash, D., Carr-Boyd, E., Bowen, D.G., Strasser, S.I., Crawford, M., Pulitano, C., and Kench, J. (2022). Association between vessels that encapsulate tumour clusters vascular pattern and hepatocellular carcinoma recurrence following liver transplantation. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.997093"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"101874","DOI":"10.1016\/j.jhepr.2026.101874","article-title":"Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab\u2013bevacizumab","volume":"8","author":"Sayadi","year":"2026","journal-title":"JHEP Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/PAP.0000000000000501","article-title":"Advances in Hepatocellular Carcinoma: Molecular Insights, Histologic Subtypes, and Differential Diagnosis","volume":"32","author":"Zheng","year":"2025","journal-title":"Adv. Anat. Pathol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jhep.2026.03.019","article-title":"Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French genomic medicine initiative","volume":"85","author":"Campani","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Liu, Y., Yang, H., Li, T., and Zhang, N. (2024). Immunotherapy in liver cancer: Overcoming the tolerogenic liver microenvironment. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1460282"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.7150\/ijms.117603","article-title":"Single-Gene Mutations in Hepatocellular Carcinoma: Applications and Challenges in Precision Medicine","volume":"22","author":"Yu","year":"2025","journal-title":"Int. J. Med. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and non-inflamed classes of HCC: A revised immunogenomic classification","volume":"72","author":"Montironi","year":"2022","journal-title":"Gut"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat. Med."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Yang, H., Liu, Y., Zhang, N., Tao, F., and Yin, G. (2024). Therapeutic advances in hepatocellular carcinoma: An update from the 2024 ASCO annual meeting. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1453412"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1200\/JCO.2024.42.16_suppl.4109","article-title":"Association between beta-catenin (CTNNB1) mutations and clinical outcomes of pembrolizumab in advanced hepatocellular carcinoma (aHCC): Exploratory analyses from KEYNOTE-240","volume":"42","author":"Kudo","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1200\/JCO.2024.42.16_suppl.4106","article-title":"Impact of CTNNB1 alterations on outcomes in patients with hepatocellular carcinoma (HCC)","volume":"42","author":"Pai","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1478-3231.2011.02640.x","article-title":"MRI features of hepatocellular carcinoma expressing progenitor cell markers","volume":"32","author":"Jeong","year":"2011","journal-title":"Liver Int."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1007\/s00330-020-06675-2","article-title":"MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma","volume":"30","author":"Hectors","year":"2020","journal-title":"Eur. Radiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3748\/wjg.v29.i1.43","article-title":"Current status and future perspectives of radiomics in hepatocellular carcinoma","volume":"29","author":"Miranda","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S1470-2045(23)00468-0","article-title":"Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab\u2013bevacizumab in patients with hepatocellular carcinoma: A multicentre retrospective study","volume":"24","author":"Zeng","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"S255","DOI":"10.3350\/cmh.2024.0541","article-title":"Liquid biopsy in hepatocellular carcinoma: Challenges, advances, and clinical implications","volume":"31","author":"Park","year":"2025","journal-title":"Clin. Mol. Hepatol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3115\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:36:15Z","timestamp":1790339775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":97,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cancers18193115"],"URL":"https:\/\/doi.org\/10.3390\/cancers18193115","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]}}}